I-MAB: I-Mab cuts 27% of workforce after pipeline re-prioritization

The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 and 4-1BB bispecific antibody for gastric cancers.The post I-Mab cuts 27% of workforce after pipeline re-prioritization appeared first on PharmaLive.